VIEWS AND ANALYSIS, PHARMACY MARKET

Streamlining Distribution in the Pharmaceutical Industry

November 25, 2022

Streamlining Distribution
Satyendra Sinha is a Functional Consultant with the TCS Life Sciences unit, and focuses on order management, distribution. 

Spotlight

Trio Medicines LTD

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

OTHER WHITEPAPERS
news image

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Read More
news image

High Pressure Homogenizer for Nano-formulation

whitePaper | December 16, 2022

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, utilizes interaction high-pressure microfluidic jet technology, and it is equipped with highly modular power and processing units.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

How to Choose the Right Contract Manufacturing Organisation for Your Pharmaceutical Product

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

Read More
news image

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Read More

Spotlight

Trio Medicines LTD

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Events